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Fibrinolysis and coagulation were studied in 10 neonates undergoing 
cardiac operations for congenital heart defects. Coagulation was activated 
during cardiopulmonary bypass as evidenced by highly increased pro- 
thrombin fragment 1+2 levels compared with preoperative values. Pro- 
thrombin fragment 1+2 levels remained elevated until postoperative day 3. 
Unlike coagulation, fibrinolysis was not activated uring cardiopulmonary 
bypass but did show late activation on postoperative day 3, as evidenced by 
elevated levels of the fibrin degradation product D-dimer. Lack of fibrino- 
lytic activation during bypass and its appearance on postoperative day 3 
were partly explained by changes observed in tissue plasminogen activator 
and its inhibitor. During bypass, levels of tissue plasminogen activator and 
its inhibitor increased by 3.4-fold and 3.2-fold, respectively. In the postop- 
erative period, levels of plasminogen activator inhibitor normalized rapidly 
whereas tissue plasminogen activator emained elevated, resulting in late 
fibrinolytic activation on postoperative day 3. In accordance with elevated 
prothrombin fragment 1+2, platelet count, antithrombin III, protein C, 
prothrombin, and factor VII were decreased on postoperative day 2, 
indicating ongoing consumptive coagulopathy. Nine patients had anti- 
thrombin I I I  and six had protein C levels below age-specific normal ranges, 
consistent with an acquired deficiency state. Three had central venous 
thrombosis by postoperative day 4 or 5. In all three, thrombosis was 
preceded by antithrombin Ill deficiency, protein C deficiency, and highly 
elevated plasminogen activator inhibitor (3.7 to 37 times the mean of the 
other patients) on postoperative days 1 to 3. In conclusion, cardiopulmo- 
nary bypass in neonates caused rapid and profound alterations i  the 
coagulation and fibrinolytic systems and initiated consumptive coagulopa- 
thy lasting until at least postoperative day 3. Thrombophilic abnormalities 
in antithrombin III, protein C, and fibrinolysis were frequently found and 
were associated with serious thrombotic omplications. (J Thorac Cardio- 
vasc Surg 1996;112:665-71) 
C ardiopulmonary bypass (CPB) causes multiple 
alterations in the hemostatic system. These in- 
clude alterations in platelet function, coagulation 
factors, fibrinolytic system, and physiologic inhibi- 
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tors of coagulation. 1-s As a consequence, perioper- 
ative and postoperative bleeding, as well as early 
thrombotic events, may constitute significant prob- 
lemsg' 9, 10 These problems are especially frequent 
in neonates, and the need for blood products i
greater in the neonates and young infants than in 
older children. TM 12 The hemostatic system of a 
neonate is immature and different from that of an 
adult.13, 14 Therefore information obtained from 
studies in adults and older children may have limited 
application to neonates. However, studies of hemo- 
sta ic effects of CPB in neonates are remarkably 
few.Z, 15 To elucidate the mechanisms of bleeding 
and thrombotic omplications, we investigated the 
coagulation and fibrinolytic systems during and after 
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CPB and also evaluated the behavior of the two 
main physiologic anticoagulants, antithrombin I I I  
and protein C, in neonates undergoing cardiac op- 
erations for congenital heart defects. 
Patients and methods 
Patients. The patient series is composed of 10 consec- 
utive term neonates who had cardiac operations at our 
hospital between October 1994 and February 1995. The 
ages of the patients varied from 4 to 14 days (mean 8 
days). There were seven boys and three girls. The cardiac 
defects were as follows: transposition of great arteries 
without additional significant defects (n = 4), transposi- 
tion and ventricular septal defect (n = 3), transposition, 
ventricular septal defect, and aortic coarctation (n = 1), 
aortic valvular stenosis (n = 1), and transposition and 
double-outlet right ventricle (n = 1). 
Operations and CPB. Standardized surgical and CPB 
techniques were used, with core cooling down to 15 ° to 
24 ° C. In association with circulatory arrest (n = 3), 
hypothermia varied from 15 ° to 18 ° C. Cold blood cardio- 
plegia was used for myocardial preservation. Before the 
aorta was unclamped, a warm cardioplegic solution ("hot 
shot"; 100 ml Plegisol solution + 100 ml whole blood + 
440 mg glutamate + 440 mg aspartate + 20 mg allopuri- 
nol + 2 mmol potassium chloride, dose 300 ml/m 2, 
temperature 34 ° to 37 ° C) was administered. The anes- 
thetics consisted of alfentanil and midazolam by infusion 
and pancuronium for muscular elaxation. Whole blood, 
donated 20 to 28 hours before the operation (except for 
operations on Mondays, for which the blood was donated 
on the previous Saturday), was used to prime the CPB 
circuit (Lilliput, Sorin-Dideco, Mirandola, Italy). The 
blood was tested for antibodies against human immuno- 
deficiency and hepatitis C viruses and the presence of 
surface antigen of hepatitis B virus. Also used as a prime 
was 4% human albumin solution. The volume of the CPB 
circuit is 300 ml with 3/16-inch diameter tubes (patient 
weight less than 4 kg) and 400 ml with 1/4-inch diameter 
tubes (patient weight at least 4 kg). The dilution of the 
prime was calculated to achieve a hematocrit value of 
25%. In the calculation the blood volume of a neonate is 
estimated to be 85 ml/kg. The weights of the patients 
varied from 2.84 to 4.5 kg (mean _+ standard error of the 
mean [SEM], 3.52 - 0.202 kg) and the preoperative 
hematocrit values varied from 46% to 60% (mean -+ 
SEM, 54% --- 1.7%). Consequently, in seven patients only 
4% albumin was used for the prime. The whole volume of 
cardioplegic solution was hemofiltered, and during re- 
warming the hematocrit value was elevated to the target 
value by adding whole blood to the CPB circuit while 
continuing the hemofiltration. Thus the patients received 
525 + 96 ml (mean +- SEM) of whole blood. In five 
patients red blood cell concentrates were also used after 
CPB during the operation. Hemostasis during the opera- 
tion was supported by giving fresh frozen plasma (n = 4), 
platelet concentrates (n = 4), and/or cryoprecipitate (n = 
4) to six patients. Need for these products during CPB was 
subjectively evaluated by the surgeon and the anesthesi- 
ologist. Eight patients received factor IX concentrate, 500 
(n = 7) to 1000 IU (n = 1), in the prime at the end of CPB. 
Aprotinin was given to all patients: first 30,000 IU/kg 1 
hour after induction of anesthesia, 30,000 IU/kg into the 
prime, and 8000 IU/kg per hour during CPB. Giving factor 
IX concentrate and aprotinin reflects the current protocol 
for neonatal CPB at our hospital. Eight patients received 
amrinone (2 mg/kg loading when the aorta was opened, 
followed by 7.5 tzg/kg per minute infusion) during the 
study period. CPB time varied from 54 to 433 minutes 
(mean -+ SEM, 174 + 31 minutes). The heparin effect was 
neutralized by injecting protamine (first 2 mg/kg and then 
additional doses according to he activated clotting times). 
Activated clotting time was measured by means of high- 
range heparinase cartridges (Medtronic HemoTec, Inc., 
Englewood, Colo.). The postoperative care in the inten- 
sive care unit lasted 3 to 12 days (mean _+ SEM, 6.9 --- 1.0 
days). During intensive care, major complications oc- 
curred in six patients; one of them died, and the other five 
recovered well. Two patients underwent resternotomy 
necessitated by bleeding (surgical bleeding in one and 
nonsurgical bleeding in the other), and one patient had 
resternotomy and successful cardiopulmonary esuscita- 
tion for asystole, probably caused by an episode of pul- 
monary hypertension. Thrombosis developed in three 
patients, in the superior vena cava in two and in the 
innominate vein in one. One of these patients died on 
postoperative day 4. The other thrombi were diagnosed in 
reoperations on postoperative days 4 and 5. 
Postoperative use of blood products. During the first 3 
postoperative days all patients received red blood cells 
(mean _ SEM, 38 -+ 4 ml/kg). Additionally, seven patients 
received fresh frozen plasma (25 +_ 11 ml/kg) and three 
received platelet concentrates (3.7 to 14.7 ml/kg). 
Samples and analytic methods. The preoperative 
screening of coagulation consisted of activated partial 
thromboplastin time, prothrombin time, and platelet 
count. In the postoperative period, activated partial 
thromboplastin time and prothrombin time were mea- 
sured when clinically indicated. Hemoglobin concentra- 
tion, hematocrit value, and platelet count were analyzed 
daily. For coagulation studies, the blood was drawn 
through indwelling arterial ines. Nine volumes of blood 
were mixed with 1 volume of 0.129 mol/L trisodium 
citrate. Plasma was immediately separated by centrifuga- 
tion (1900 g for 20 minutes) and frozen at -70 ° C until 
assayed. For prothrombin fragment 1+2 (Fl+2), 0.6 ml of 
blood was collected in heparin (Microtainer, Becton Dick- 
inson & Co., Rutherford, N.J.), after which plasma was 
separated by centrifugation and stored at -70 ° C. The 
samples were collected as follows: after induction of 
anesthesia before CPB (referred to as "preoperative" 
sample), during CPB 10 minutes after the aorta was 
opened, after CPB 15 minutes after injection of prota- 
mine, and on postoperative days 1 to 3. 
Factor VII and prothrombin activities were measured 
with the one-stage method by the use of rabbit brain 
thromboplastin (Thromboplastin IS, Baxter Healthcare 
Corporation, Dade International, Inc., Miami, Fla.). The 
assays were carried out in an ACL 300 R coagulometer 
(ACL Inc., Elk Grove Village, Ill.). A frozen plasma pool 
was taken as 100% activity. Antithrombin III was mea- 
sured with the ACL 300 R coagulometer with an IL test 
antithrombin III kit from Instrumentation Laboratory 
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Table I. Coagulation parameters in the 10 patients 
F1 +2 A T III PC FVII Prothrombin Platelets 
Sample (pmol/ml ) (%) (%) (%) (%) (109/L ) 
Preoperative 1.1 +_ 0.2 44 _+ 4 26 _+ 1 55 _+ 5 55 _+ 4 352 _+ 41 
During CPB 2.6 _+ 0.3t 41 _+ 4 36 _+ 5 31 _+ 35 35 _+ 2§ 71 _+ 145 
During CPB, C 5.2 _+ 0.7§ 78 _+ 4§ 66 _+ 5§ 63 _+ 8 71 _+ 7* 139 +_ 25§ 
After CPB 4.4 _+ 0.7§ 51 _+ 4 74 _+ 12t 63 _+ 10 80 -+ 8* 99 _+ 20§ 
After CPB, C 6.6 _+ 1.0§ 77 _+ 5§ 112 _+ 20t 94 _+ 13" 123 _+ 14t 155 _+ 33§ 
POD 1 2.4 _+ 0.6* . . . .  158 _+ 295 
POD 2 1.7 _+ 0.3* 29 _+ 3"~ 21 _+ 2t 23 _+ 4§ 48 _+ 3 115 _+ 165 
POD 3 3.0 _+ 0.5t . . . .  104 _+ 225 
F1 +2, Prothrombin fragment; AT III, antithrombin III; PC, protein C; FV//, factor VII; %, percentage of normal adult mean; C, values corrected for 
hematocrit change; POD, postoperative day. Values are presented as mean -+ SEM. 
*p < 0.05 compared with preoperative valuel 
tp < 0.01 compared with preoperative value. 
,+p < 0.001 compared with preoperative value. 
§p < 0.0001 compared with preoperative value. 
S.P.A., Milan, Italy. IL calibration plasma was used as a 
standard. Protein C was measured by means of a chromo- 
genic method with S-2366 (Chromogenix AB, M61ndal, 
Sweden) used as a substrate and protein C activator 
(American Diagnostica, Inc., Greenwich, Conn.). Again, a 
frozen plasma pool was taken as 100% activity. D-dimer 
was assayed with an enzyme-linked immunosorbent assay 
method using Asserachrom D-Di from Diagnostica-Stago, 
Asnieres, France, as described by the manufacturer. Plas- 
minogen activator inhibitor (PAI) and tissue plasminogen 
activator (t-PA) were measured with Coatest PAI and 
Coatest -PA, respectively (Chromogenix AB). F1 +2 was 
measured with Thrombonostika F1.2 from Organon 
Teknika Corp., Durham, North Carolina, as described by 
the manufacturer. 
D-dimer levels were highly increased on postoperative 
day 3. Four patients had values above 4000 ng/ml, one 
above 3000 ng/ml, and two above 2000 ng/ml. Inasmuch as 
there was not enough plasma to titrate these levels 
further, these minimum estimates were used in subse- 
quent analysis. 
In the following text, "normal ranges" refer to the 
values for term healthy neonates at the age of 5 days 
reported by Andrew, Paes, and JohnstonJ 3
Correction for hemodilution. During CPB, the blood is 
diluted by the 4% albumin solution in the prime and by 
intravenous fluids. This addition of water masks the effects 
of plasma protein substitution, production or release in 
the body, and their consumption. To uncover the net 
effect of these mechanisms, the results from samples taken 
during operation were corrected for hemodilution by a 
correction factor, F, calculated by the following formulal6: 
(100 - HCtsample) " HCtpreCpB 
F= 
(100 -- HCtpreCeB ) " HCtsample 
where Hct is hematocrit. 
Statistical methods. The two-tailed Student's t test for 
paired samples or the Wilcoxon signed rank test was used 
for comparisons, andp < 0.05 was regarded as significant. 
The study protocol was approved by the ethics commit- 
tee of the Children's Hospital, University Central Hospi- 
tal of Helsinki. Informed consent was obtained from the 
parents of each patient before entry into the study. 
Results 
Activation of coagulation. Net activation of coag- 
ulation was measured as F1+2, which reflects pro- 
thrombin activation to thrombin. Behavior of F1 +2 
is shown in Table I. F l+2 increased substantially 
during CPB. The levels of F l+2 remained elevated 
during postoperative days 1, 2, and 3. Factor VII  and 
prothrombin were decreased on postoperative day 2 
(Table I). Platelet count decreased progressively 
until postoperative day 3 (Table I). 
Fibrinolysis. Results of fibrinolytic studies (t-PA, 
PAI, and D-dimer) are shown in Fig. 1. Both t-PA 
and PAI levels increased rapidly during CPB. The 
response of PAI peaked after the aorta was opened 
during CPB, whereas peak t-PA values were seen 
after the administration of protamine. The PAI level 
had already returned to normal on postoperative 
day 1, whereas t-PA levels remained significantly 
elevated on postoperative day 3. In accordance with 
an extensive but transient increase in PAI and a 
sustained t-PA increase, the D-dimer level remained 
relatively stable until postoperative day 1 but then 
sharply increased by postoperative day 3. In two 
patients, additional PAI and t-PA values were ob- 
tained from samples tarting 30 minutes before the 
"during CPB" sample and continuing on 30-minute 
intervals until the "after CPB" sample. In both 
patients the highest PAI values were seen in the first 
sample, whereas t-PA peaked in the "after CPB" 
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Fig. 1. Fibrinolytic studies in the 10 patients. Values are 
presented as mean +_ SEM. PAI values represent those of 
seven patients who were free of thrombosis. Exact D- 
dimer levels on postoperative day 3 were unknown but 
were above 2000 ng/ml or 4000 ng/ml in seven patients. In 
statistical evaluation, these cutoff points were used and 
significance was calculated by the Wilcoxon signed rank 
test. *p -< 0.05, **p -< 0.01, ***p -< 0.001 compared with 
preoperative alues. POD, Postoperative day. 
sample or in the sample preceding it (data not 
shown). Thus the PAI response would probably 
have been even faster and more pronounced if 
sampling intervals had been smaller. 
Antithrombin III and protein C. Levels of anti- 
thrombin III and protein C are shown in Table I. 
Antithrombin III was below the reference range 
(41% to 93%) in five of the 10 patients (50%) at the 
beginning of the operation and was low in nine 
patients on postoperative day 2 (90%) (Fig. 2). 
Protein C was within normal imits (20% to 64%) in 
every patient at the beginning of the operation but 
low in six patients (60%) on postoperative day 2 
(Fig. 2). 
Patients with thrombosis. Individual postopera- 
tive levels of antithrombin III, protein C, and PAI 
are shown in Fig. 2. The three patients in whom 
thrombosis developed by postoperative day 4 or 5 
had low antithrombin Ill and protein C levels on 
postoperative day 2. The behavior of PAI was highly 
abnormal. PAI values on postoperative day 1 varied 
from 70 to 700 AU/ml in the patients having throm- 
bosis, whereas the highest PAI value in thrombosis- 
free patients was 43 AU/ml. This disparity was clear 
also on postoperative day 3. Except for PAI, the 
pattern of changes in studied parameters (including 
F1+2) did not differ between patients with and 
without hrombosis. The abnormal behavior of PAI 
in the patients with thrombosis was seen only in the 
postoperative period. During and before CPB, PAI 
values in these three patients were within the range 
of the rest of the patients. 
Discussion 
This is the first study to demonstrate a rapid t-PA 
release counteracted by an even faster rise in PAI 
during neonatal CPB. PAI normalized rapidly in 
patients who were free of thrombosis, whereas t-PA 
remained elevated. Thus, despite t-PA release, en- 
dogenous fibrinolysis was inhibited uring the oper- 
ation. Moreover, after normalization of PAI, fibri- 
nolysis was activated in the late postoperative p riod 
(postoperative day 3), as evidenced by the highly 
elevated levels of fibrin degradation product D- 
dimer. 
We believe that these observations of t-PA and 
PAI changes are not affected by the use of aprotinin. 
Aprotinin inhibits serine proteases including plas- 
min, but there is no evidence that aprotinin would 
affect he release of either t-PA or PAI from endo- 
thelium. 
We are familiar with only one relevant study of 
fibrinolysis in neonates, where increase in t-PA and 
fibrin degradation products during neonatal extra- 
corporeal ife support was observed only after 48 
hours. 15 However, the sampling intervals in that 
study were such that early and transient changes in 
fibrinolysis could easily have been missed. 
Surgical stress causes intraoperative t-PA re- 
lease, 17 and this has been seen also during CPB. Ia 19 
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Fig. 2. Individual values of antithrombin III (ATIII), protein C (PC), and PAL The dotted lines refer to 
reported normal ranges for antithrombin III and protein C. 16 Open triangles refer to patients with 
thrombosis. 
However, net activation of fibrinolysis during CPB is 
rarely seen, 6 as was the case also in our study. In 
addition to the observed physiologic fibrinolytic 
shutdown, fibrinolysis was further inhibited by apro- 
tinin, which inhibits plasmin action. It is not possible 
to quantitate the relative contribution of these two 
simultaneous inhibitory mechanisms to net fibrino- 
lysis. However, it can be concluded that inasmuch as 
fibrinolysis was inhibited both physiologically and 
pharmacologically during CPB, hyperfibrinolysis 
was probably not a cause of bleeding during the 
operations. Thus additional antifibrinolytic drugs 
may be of little value during CPB in neonates, 
although this theory needs to be tested in future 
studies. Unlike during the operation, fibrinolysis was 
activated after the operation. Because of sustained 
t-PA release, hyperfibrinolysis may contribute to 
late postoperative bleeding complications. 
CPB activates coagulation. The indicators of 
thrombin formation and/or action like Fl+2, fibri- 
nopeptide A, soluble fibrin monomer, and anti- 
thrombin III-thrombin complexes are elevated at 
the end of CPBJ' 15, 2o This was clearly seen also in 
the present study. However, it is not as clear for how 
long and how often this activation continues during 
intensive care. Obviously, individual patients and 
patient populations differ from each other. Many 
factors especially prominent in neonates, for exam- 
ple, hemodynamic lability resulting in tissue hypo- 
perfusion, hepatic immaturity, and infections, may 
trigger or maintain disseminated intravascular coag- 
ulation. One of our patients had a resternotomy 
because of diffuse bleeding on the day of the oper- 
ation. Otherwise we observed no overt postopera- 
tive bleeding. FI+ 2 was elevated in every postoper- 
ative sample and even rose from postoperative day 2 
to postoperative day 3. Levels of antithrombin III, 
protein C, prothrombin, and factor VII were de- 
creased. Progressive thrombocytopenia, increased 
t-PA release, and high levels of fibrin degradation 
products were also present. 
Our findings of activated coagulation and fibrino- 
lysis associated with decrease in several coagulation 
factors are consistent with subclinical disseminated 
intravascular coagulation until at least postoperative 
day 3. We believe that this subclinical consumptive 
coagulopathy may be important for two reasons. 
First, in addition to the bleeding risk in the area of 
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the operation, sick neonates are at risk for intracra- 
nial hemorrhageY Second, there is a risk of throm- 
bosis. 
Eight patients received factor IX concentrate at
the end of CPB, which might have influenced the 
measured hemostatic variables. However, we could 
not observe such an effect because the patterns of 
coagulation and fibrinolysis changes in the two 
patients who did not receive factor IX concentrate 
were essentially the same as in the rest of the 
patients. For example, the two patients without 
factor IX concentrate had 7.2-fold and 4.2-fold 
increases in F l+2 level at the end of the opera- 
tion and on postoperative day 3, respectively, 
compared with the preoperative l vels (data not 
shown). Eight patients received amrinone, which 
may have influenced the degree of thrombocyto- 
penia.21, 22 
Antithrombin III and protein C are central phys- 
iologic anticoagulants. Deficiencies of antithrombin 
III and protein C may cause thrombosis during the 
neonatal period. 24'25 Data concerning effects of 
neonatal CPB on anticoagulant levels is sparse and 
inconsistent. Kern and associates 2 found higher 
levels of antithrombin III in the postoperative p - 
riod compared with the preoperative alues but did 
not indicate how many patients had values below the 
normal range for age. Boldt and coworkers 1 found 
that antithrombin III decreased from a mean pre- 
operative value of 77% to 58% in neonates and 
small infants but provided no data on individual 
levels. They also found low postoperative concen- 
trations of protein C. 
In the present study, the pattern of antithrombin 
III and protein C changes was very constant from 
patient to patient. The administered blood and 
blood products maintained the concentrations of
these proteins almost invariably in the normal 
range during CPB despite hemodilution. Actually, 
the values corrected for hemodilution showed that 
the absolute amounts of antithrombin III and 
protein C in the circulation were, respectively, 1.8 
and 4.3 times the amounts measured in the pre- 
operative period. Despite this iatrogenic increase, 
both antithrombin III and protein C decreased in
the postoperative period. The mechanism was 
most likely consumption. Individual postoperative 
values were consistent with the deficiency state in 
90% and 60% of the patients for antithrombin III
and protein C, respectively. Antithrombin III 
deficiency was already present preoperatively in 
50% of the patients. In conclusion, a majority of 
the patients had at least two thrombophilic coag- 
ulation abnormalities. 
Central venous thrombosis developed for up to 5 
days after the operation in three patients--fatal in 
one and nonfatal in the other two. Inasmuch as the 
diagnosis of thrombosis was clinical, occurrence of 
additional subclinical thrombi cannot be excluded. 
This high rate of thrombosis eems coincidental, 
because the patient care was unaltered from our 
routine care, and during the past 10 years our 
incidence of clinical thrombosis has been 5.8% in 
neonates and 0.6% in older children after CPB. 
Thrombogenesis has a multifactorial background 
and is probably most often triggered by central 
venous catheters. 1°'26 Every patient in our series 
had a central venous line and the catheters probably 
were the most important factors in the development 
of thrombosis. However, we believe that the com- 
plicated coagulopathy contributed to thrombogen- 
esis as well. Antithrombin III and protein C defi- 
ciencies were present in all three patients before 
thrombosis. The most striking finding was extremely 
high values of PAI both in absolute terms and in 
comparison with the values in patients who were 
thrombosis-free. Actually, the PAI value of 700 
AU/ml is the highest value ever measured in our 
coagulation laboratory. The PAI probably origi- 
nated from the endothelium, because platelet-de- 
rived PAI is inactive in t-PA activity-based assays. 27 
This high release of PAI seemed to be a specific 
postoperatively acquired fibrinolytic disorder of the 
endothelium, since postoperative t-PA values and 
preoperative PAI values in the patients with throm- 
bosis were similar to those of the patients not having 
thrombosis. We conclude that high levels of PAI 
during the days when thrombi were developing most 
likely contributed to the thrombogenesis in the 
three patients. Further, PAI measurement onpost- 
operative days 1 and 3 elegantly predicted which 
patients would have thrombosis. However, this pre- 
dictive property of PAI measurement eeds to be 
reproduced in a larger prospective study with detec- 
tion also of subclinical thrombi. 
To summarize, neonatal CPB was associated with 
sustained consumptive coagulopathy and activated 
fibrinolysis during the immediate postoperative 
phase. This resulted in deficiencies of both anti- 
thrombin III and protein C in the majority of 
patients. These deficiencies, in association with ab- 
normal inhibition of fibrinolysis, were associated 
with severe thrombotic complications. Future stud- 
ies of neonates are needed to minimize the trauma 
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to blood caused by CPB and to assess the value of 
different herapeutic approaches to the coagulopa- 
thy. Specifically, serial measurements of antithrom- 
bin III, protein C, and PAI  and replacement therapy 
for observed deficiencies may be indicated in this 
patient group at high risk of postoperative throm- 
bosis. 
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